Relay Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US75943R1023 (RLAY)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €7.17M
    Gross margin
    1.3%
    EBIT
    -€294.50M
    EBIT margin
    -4,105.6%
    Net income
    -€267.45M
    Net margin
    -3,728.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €8.61M +20.1% -€255.53M -4.5%
    €26.56M +208.4% -€287.28M +12.4%
    €11.52M -56.6% -€312.10M +8.6%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Adams Brian Chief Legal Officer -20K $3.68 -$73.28K
    Bergstrom Donald A President, R&D -31K $3.69 -$113.54K
    Catinazzo Thomas Chief Financial Officer -20K $3.69 -$74.10K
    Rahmer Peter See remarks -17K $3.68 -$62.87K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.3M $5.96M +727K Buy

    Add to watchlist

    Notifications